RxDoctor Payments Data

Robert Martin

Family · Lancaster, PANPI 1376541813

Payments from drug & device makers

$1,187in general payments, 2019–2025

Across 56 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$761
  • E.r. Squibb & Sons, L.L.C.$124
  • Pfizer$100
  • Ardelyx, Inc.$96
  • Bristol Myers Squibb$47
  • Heron Therapeutics, Inc.$27
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$1,187100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,187 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$31,574
Medicare patients
280
Services billed
377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide74$68,065
XifaxanRifaximin19$59,011
CreonLipase/Protease/Amylase13$28,259
Mesalamine22$23,468
Dexlansoprazole DrDexlansoprazole28$7,927
Omeprazole373$4,709
Pantoprazole Sodium198$3,441
Lubiprostone14$2,965
Famotidine262$2,532
Colestipol Hcl23$1,675
Ursodiol11$1,514
Esomeprazole Magnesium41$1,317
Dicyclomine Hcl28$574
Balsalazide Disodium12$457
Cimetidine11$365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$761$96,32487 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,717 family providers in Pennsylvania.

Other family in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →